Dr. Kahl on the Current Treatment Landscape in Relapsed/Refractory iNHL

Video

Brad S. Kahl, MD, discusses the current treatment landscape in ​relapsed/refractory indolent non-Hodgkin lymphoma.

Brad S. Kahl, MD, a medical oncologist at Siteman Cancer Center and a professor of medicine in the Division of Oncology at Washington University School of Medicine in St. Louis, discusses the current treatment landscape in ​relapsed/refractory indolent non-Hodgkin lymphoma (iNHL).

The management of patients with ​relapsed/refractory iNHL can be challeng​ing as many factors influence the decision-making process, says Kahl. 

Patient-specific factors such as age, comorbidities, and goals of treatment should be considered, Kahl explains. Additionally, it is important to note all prior treatments the patient had received and how well they responded to them. 

Notably, if a patient ​derived a substantial response from a frontline therapy with minimal toxicity, it may be reasonable to offer that therapy again. However, ​as there are many ​therapeutic options in this space, this does not happen often, Kahl concludes.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute